These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26275578)

  • 21. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
    Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
    Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.
    Litwin AH; Drolet M; Nwankwo C; Torrens M; Kastelic A; Walcher S; Somaini L; Mulvihill E; Ertl J; Grebely J
    J Viral Hepat; 2019 Sep; 26(9):1094-1104. PubMed ID: 31074167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tensions in relation: How peer support is experienced and received in a hepatitis C treatment intervention.
    Bonnington O; Harris M
    Int J Drug Policy; 2017 Sep; 47():221-229. PubMed ID: 28606391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs.
    Treloar C; Hull P; Bryant J; Hopwood M; Grebely J; Lavis Y
    Drug Alcohol Depend; 2011 Jul; 116(1-3):52-6. PubMed ID: 21194852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
    Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study.
    Fortier E; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Bruneau J; Grebely J;
    Int J Drug Policy; 2015 Nov; 26(11):1094-102. PubMed ID: 26145482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peer involvement and cross-sector efforts in establishing integrated treatment of hepatitis C virus infection for people with substance use disorders: experiences from Norway.
    Lygren OJ; Bjørnestad R; Løberg EM; Bonnier ML; Buljovcic VB; Johansson KA; Fadnes LT;
    Subst Abuse Treat Prev Policy; 2019 Dec; 14(1):58. PubMed ID: 31864396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
    Radley A; Tait J; Dillon JF
    Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program.
    Butner JL; Gupta N; Fabian C; Henry S; Shi JM; Tetrault JM
    J Subst Abuse Treat; 2017 Apr; 75():49-53. PubMed ID: 28237054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C testing and status among opioid substitution treatment clients in New South Wales.
    Shand FL; Day C; Rawlinson W; Degenhardt L; Martin NG; Nelson EC
    Aust N Z J Public Health; 2014 Apr; 38(2):160-4. PubMed ID: 24690055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
    BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy.
    Jerkeman A; Norkrans G; Lidman C; Westin J; Lagging M; Frimand J; Simonsberg C; Kakko J; Widell A; Björkman P
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):523-31. PubMed ID: 24637496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
    Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
    Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.